Antibodies targeting tumor associated macrophages and uses thereof

US11186634B2 · kind B2 · utility

Assignees

• INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) · FR
• UNIVERSITE PAUL SABATIER—TOULOUSE III · FR
• CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE · FR
• CENTRE HOSPITALIER UNIVERSITAIRE DE TOULOUSE · FR
• Institut Claudius Regaud · FR

Inventors

• Mary Poupot · Toulouse, FR
• Loïc Ysebaert · Toulouse, FR
• Marie Tosolini · Toulouse, FR
• Jean-Jacques Fournie · Ramonville-Saint-Agne, FR
• Pierre Brousset · Toulouse, FR
• Philippe Rochaix · Toulouse, FR

Key dates

• Filing date: Jul 28, 2017
• Grant date: Nov 30, 2021
• Expiry date: Nov 10, 2038

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/732
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to antibodies targeting Tumor Associated Macrophages (TAMs) and uses thereof. The inventors investigated specific marker exposed on the surface of the macrophages associated to tumor in order to detect and target TAMs. They showed that sideroflexin 3, which is absent in normal macrophage, is expressed by tumor associated macrophages. The inventors further demonstrated that using antibody directed to sideroflexin 3, they depleted TAMs in PBMC sample obtained from LCC patient, and strongly reduced leukemic B cells number.